MedTrace Logo

Misoprostol for Reduction of Blood Loss During Fibroid Surgery

NCT02209545 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-09-07

Study results available
· View outcomes & findings →

Summary

The aim of this research work is to assess the impact of a single preoperative dose of buccal misoprostol in reducing blood loss during abdominal fibroid surgery.

Conditions

  • Fibroids

Interventions

DRUG

Misoprostol

25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.

DRUG

Placebo

25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.

Sponsors & Collaborators

Principal Investigators

  • Magdy Milad, MD · Northwestern University, Northwestern Memorial Hopsital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02209545 on ClinicalTrials.gov